ISSN: 2161-0681

Revista de patología clínica y experimental

Acceso abierto

Nuestro grupo organiza más de 3000 Series de conferencias Eventos cada año en EE. UU., Europa y América. Asia con el apoyo de 1.000 sociedades científicas más y publica más de 700 Acceso abierto Revistas que contienen más de 50.000 personalidades eminentes, científicos de renombre como miembros del consejo editorial.

Revistas de acceso abierto que ganan más lectores y citas
700 revistas y 15 000 000 de lectores Cada revista obtiene más de 25 000 lectores

Indexado en
  • Índice Copérnico
  • Google Académico
  • sherpa romeo
  • Abrir puerta J
  • Revista GenámicaBuscar
  • TOC de revistas
  • Directorio de publicaciones periódicas de Ulrich
  • Búsqueda de referencia
  • Universidad Hamdard
  • EBSCO AZ
  • OCLC-WorldCat
  • publones
  • Fundación de Ginebra para la educación y la investigación médicas
  • Pub Europeo
  • ICMJE
Comparte esta página

Abstracto

A Retrospective Study of the Incidence of GIST in Scotland from 1995 to 1999

Graham JS, Nowicki S, Dunbar G, Cowie F, Dick C, R Reid, Walsh S, White JD and Boyd K

Background and aims: Gastrointestinal Stromal Tumours (GIST) are mesenchymal soft tissue neoplasms which express the c-kit receptor and are exquisitely sensitivity to tyrosine kinase receptor inhibitors such as imatinib. This has significantly improved prognosis so it is important to identify retrospective cases. Methods: Patients between 1995-1999 with suspected GIST were identified via Scottish pathology departments. C-kit + and C-kit -/CD34 + tumours were included. Data were analysed according to NIH consensus and the newer AFIP criteria. Results: The incidence of GIST was 0.69/100000/year. 44.8% were originally diagnosed as GISTs. Using NIH Consensus criteria there was a statistically significant relationship between overall survival and necrosis (p=0.004), prognostic group (p<0.0001) and mitotic rate (p=<0.0001). Overall survival was correlated with AIFP criteria (p value <0.0001). Conclusion: This pan Scotland study validates the AFIP criteria for assessment of overall survival in GISTs. In addition using the established NIH consensus criteria confirms a similar incidence to other European countries. We have identified patients who are eligible for targeted therapies who would otherwise have been missed.